Privacy Policy
Signals Blog

Contributors

Categories

Improving the efficiency of gene targeting in blood stem cells

As mentioned in the introductory post to this series on blood stem cell gene therapy, several significant issues existed with the first set of clinical trials in the gene therapy world. It became abundantly clear that simply delivering the gene target on its own would...

Obtaining more target cells for gene therapy

Blood stem cells are the fundamental component of regenerative medicine applications involving the blood and immune system. Despite significant efforts and investment, the research community has largely failed to maintain fully functional blood stem cells for...

Stem cell training – Supplementary resources

Starting work on a new research project can be overwhelming. This is especially true in the stem cell field, with its complexities and rapid evolution. It is quite easy to get lost while conducting literature searches or looking for specific protocols, making it feel...

Communicating new science in a crisis

On most days, scientific discoveries are not cover stories or even top headlines. That hasn’t been the case since COVID-19 hit our collective consciousness. We are being inundated with science news, which would be great under different circumstances. But communicating...

Could stem cells be enlisted to battle COVID-19?

Earlier this month, Chinese media reported that doctors in Yunnan cured a patient from coronavirus with a stem cell transplant. But did they really and do stem cells actually hold promise against the new virus wreaking havoc across the world? The global pandemic has...

Cell therapies: how much will we pay?

Dr. Chih Wei Teng is Chief Operating Officer for CCRM Australia and wrote this blog with colleagues Alex Barrington and Dr. Emma Gallaher. To subscribe to the CCRM Australia newsletter: Click here  As stem cell therapies move through clinical trials and get closer to...

Subscribe to Signals

Subscribe to our blog list to receive the latest news and updates.

You have Successfully Subscribed!